First-in-class oral PDE4 prodrug with enhanced gastrointestinal safety and superior anti-inflammatory efficacy.
PALI-2108 is a novel prodrug designed to overcome the dose-limiting GI toxicity of traditional PDE4 inhibitors while maintaining potent anti-inflammatory activity.
Precision activation in inflamed tissue minimizes systemic exposure
PALI-2108 is absorbed intact in the GI tract with minimal local irritation.
Enzymatic cleavage in inflamed tissues releases active metabolite.
Potent suppression of pro-inflammatory cytokines (TNF-α, IL-17, IL-23).
Safety established in 48 healthy volunteers
Psoriasis efficacy study (n=120) – Q3 2025
Ulcerative colitis – Q1 2026
Bioavailability
GI Safety Improvement
Therapeutic Index
2025
Tissue-specific PDE4 inhibition via prodrug activation
2024
Design and synthesis of PALI-2108
Ongoing
Phase IIa psoriasis study protocol
Expanding beyond dermatology into high-unmet need inflammatory diseases
Ulcerative Colitis, Crohn's
Joint + Skin Efficacy
Multiple Sclerosis
Age 6+